anthony mato, md, msce, examines different treatment approaches to btk inhibitor intolerance
Published 3 years ago • 116 plays • Length 2:24Download video MP4
Download video MP3
Similar videos
-
2:59
anthony mato, md, msce, elaborates on outcomes from the bruin trial presented at ash 2020
-
8:44
btki inhibitors in the treatment of b-cell lymphoma - anthony mato session
-
59:49
rebooting the btk inhibitor sequence in mcl
-
2:40
dtrm-555: combining a btk inhibitor, mtor inhibitor and imid in b-cell lymphomas
-
2:48
btk inhibitors in the treatment of dlbcl: trials investigating these agents
-
1:32
selecting btk inhibitors for patients with mcl
-
0:48
jeffrey sharman, md, on the benefits of zanubrutinib as compared to other btk inhibitors
-
3:27
btk inhibitor treatment side effects | what cll patients should know
-
8:43
understanding chronic lymphocytic leukemia with anthony mato, md
-
1:18
pirtobrutinib: the next generation of btk inhibitors
-
1:10
next-generation btk inhibitors and their value in cll
-
1:43
clinical rationale for tki choice in mrcc
-
5:59
differentiating btk inhibitor mechanisms of action in mcl
-
3:36
distinguishing features among btk inhibitors
-
1:17
dr. woyach on btk inhibition and the mechanism of action of ibrutinib
-
2:57
second-generation btk inhibitors and their clinical impact
-
2:42
therapeutic options in newly diagnosed mrcc
-
5:30
rationale for btk inhibition in cll
-
3:25
btk inhibitors in cll: treatment selection